Novartis buys rights to new antibiotic
Novartis AG has bought worldwide rights to a new antibiotic drug developed by US company Paratek Pharmaceuticals to treat drug-resistant bacteria such as MRSA.
Novagali Pharma has entered into agreement with Ardeo Health for Nova23041 in the US and Canada with OCuSOFT.